Milestone Pharmaceuticals to Present Etripamil Clinical Data at Cardiology Conferences

• Milestone Pharmaceuticals will present etripamil clinical data and trial updates at three cardiology conferences from October 22 through November 9, 2026.
• Cardamyst, its etripamil nasal spray, has FDA approval to restore sinus rhythm in adults experiencing acute symptomatic paroxysmal supraventricular tachycardia (PSVT).
• October 22 presentations will address minimal blood pressure effects in PSVT and Phase 3 trial design for atrial fibrillation with rapid ventricular rate.
• A November 2 presentation will cover pooled efficacy, safety and test-dose tolerability findings for acute PSVT across multiple clinical trials.
• The November 7 presentation will examine etripamil use in RAPID study patients with recurrent PSVT following prior ablation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Milestone Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190800PRIMZONEFULLFEED9847716) on October 19, 2026, and is solely responsible for the information contained therein.